Anti-Human CD20 (Ocrelizumab) (C3150-50mg)

CD20 is a transmembrane protein that is prominently present on the surface of B-cells from the early to mature stages, but notably absent on hematopoietic stem cells, pro-B cells, or plasma cells. Its significance lies in its role in B-cell functions such as activation and differentiation. It is a key target for monoclonal antibodies used in the treatment of B-cell- related diseases and autoimmune conditions. Monoclonal antibodies targeting CD20 have been widely used to treat B-cell lymphomas, leukemias, and autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. These antibodies work by selectively targeting and depleting B-cells that express CD20, thereby modulating the immune response and reducing inflammation. This targeted approach has shown promising results in managing various B-cell disorders and has significantly improved the prognosis for patients with these conditions1,2. RG 1594, also known as ocrelizumab, is a humanized monoclonal antibody that targets CD20, a protein found on the surface of B cells. By binding to CD20, ocrelizumab helps in the depletion of B cells, which are believed to play a role in the development of sclerosis. This therapeutic approach has been found to be effective in reducing the progression of disability and lowering the frequency of relapses in patients with multiple sclerosis (MS)3-8.